Skip to main content
. 2024 Jun 15;32(2):155–167. doi: 10.38212/2224-6614.3501

Table 5.

Anti-angiogenic activity of compounds 7, 8, and 21 in human endothelial progenitor cells.

Compounds IC50 (μM) a
7 0.44 ± 0.01***
8 0.47 ± 0.03***
21 0.53 ± 0.01***
Sorafenib 5.50 ± 1.50
a

Human endothelial progenitor cells were treated with the indicated compounds for 48 h. Anti-angiogenic activity was evaluated in a cell growth assay. Data are displayed as the mean ± SEM. Sorafenib, a well-known anti-angiogenic agent, was used as a positive control.